Literature DB >> 8563754

The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9.

J Borrow1, A M Shearman, V P Stanton, R Becher, T Collins, A J Williams, I Dubé, F Katz, Y L Kwong, C Morris, K Ohyashiki, K Toyama, J Rowley, D E Housman.   

Abstract

The t(7;11)(p15;p15) translocation is a recurrent chromosomal abnormality associated primarily with acute myeloid leukaemia (FAB M2 and M4). We present here the molecular definition of this translocation. On chromosome 7 positional cloning revealed the consistent rearrangement of the HOXA9 gene, which encodes a class I homeodomain protein potentially involved in myeloid differentiation. On chromosome 11 the translocation targets the human homologue of NUP98, a member of the GLFG nucleoporin family. Chimaeric messages spliced over the breakpoint fuse the GLFG repeat domains of NUP98 in-frame to the HOXA9 homeobox. The predicted NUP98-HOXA9 fusion protein may promote leukaemogenesis through inhibition of HOXA9-mediated terminal differentiation and/or aberrant nucleocytoplasmic transport.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8563754     DOI: 10.1038/ng0296-159

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  93 in total

1.  Sequence analysis and tissue specific expression of human HOXA7.

Authors:  M H Kim; H Jin; E Y Seol; M Yoo; H W Park
Journal:  Mol Biotechnol       Date:  2000-01       Impact factor: 2.695

2.  Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b).

Authors:  N Kakazu; I Shinzato; Y Arai; S Gotoh; A Matsushita; T Ishikawa; K Nagai; T Takahashi; T Ohno; T Tsuchiya; M Ohki; T Abe
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

3.  A classification-based machine learning approach for the analysis of genome-wide expression data.

Authors:  James Lyons-Weiler; Satish Patel; Soumyaroop Bhattacharya
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

4.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

5.  CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein.

Authors:  Yue Zhang; Giovanni Morrone; Jianxuan Zhang; Xiaoai Chen; Xiaoling Lu; Liang Ma; Malcolm Moore; Pengbo Zhou
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

6.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

7.  Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation.

Authors:  Ulka Vijapurkar; Neal Fischbach; Weifang Shen; Christian Brandts; David Stokoe; H Jeffrey Lawrence; Corey Largman
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

10.  HOX expression patterns identify a common signature for favorable AML.

Authors:  M Andreeff; V Ruvolo; S Gadgil; C Zeng; K Coombes; W Chen; S Kornblau; A E Barón; H A Drabkin
Journal:  Leukemia       Date:  2008-07-31       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.